384 related articles for article (PubMed ID: 9670274)
1. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNF alpha and melphalan: Swedish experience.
Hafström L; Naredi P
Recent Results Cancer Res; 1998; 147():120-6. PubMed ID: 9670274
[TBL] [Abstract][Full Text] [Related]
2. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan.
Lindnér P; Fjälling M; Hafström L; Kierulff-Nielsen H; Mattsson J; Scherstén T; Rizell M; Naredi P
Eur J Surg Oncol; 1999 Apr; 25(2):179-85. PubMed ID: 10218462
[TBL] [Abstract][Full Text] [Related]
3. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.
de Vries MR; Borel Rinkes IH; van de Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Vahrmeijer AL; Eggermont AM
Recent Results Cancer Res; 1998; 147():107-19. PubMed ID: 9670273
[TBL] [Abstract][Full Text] [Related]
4. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
5. Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases.
De Vries MR; Borel Rinkes IH; Swaak AJ; Hack CE; Van De Velde CJ; Wiggers T; Tollenaar RA; Kuppen PJ; Eggermont AM
Eur J Clin Invest; 1999 Jun; 29(6):553-60. PubMed ID: 10354218
[TBL] [Abstract][Full Text] [Related]
6. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
Libutti SK; Barlett DL; Fraker DL; Alexander HR
J Am Coll Surg; 2000 Nov; 191(5):519-30. PubMed ID: 11085732
[TBL] [Abstract][Full Text] [Related]
7. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.
Alexander HR; Bartlett DL; Libutti SK; Fraker DL; Moser T; Rosenberg SA
J Clin Oncol; 1998 Apr; 16(4):1479-89. PubMed ID: 9552055
[TBL] [Abstract][Full Text] [Related]
8. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
9. The past decade of experience with isolated hepatic perfusion.
Grover A; Alexander HR
Oncologist; 2004; 9(6):653-64. PubMed ID: 15561809
[TBL] [Abstract][Full Text] [Related]
10. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan.
Zwaveling JH; Hoekstra HJ; Maring JK; v Ginkel RJ; Schraffordt Koops H; Smit AJ; Girbes AR
Nephron; 1997; 76(2):146-52. PubMed ID: 9200405
[TBL] [Abstract][Full Text] [Related]
11. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
Kettelhack C; Hohenberger P; Schlag PM
Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
[TBL] [Abstract][Full Text] [Related]
12. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
Kettelhack C; Hohenberger P; Schlag PM
Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
[TBL] [Abstract][Full Text] [Related]
13. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
Bartlett DL; Libutti SK; Figg WD; Fraker DL; Alexander HR
Surgery; 2001 Feb; 129(2):176-87. PubMed ID: 11174711
[TBL] [Abstract][Full Text] [Related]
14. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
[TBL] [Abstract][Full Text] [Related]
15. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.
Rothbarth J; Tollenaar RA; Schellens JH; Nortier JW; Kool LJ; Kuppen PJ; Mulder GJ; van de Velde CJ
Eur J Cancer; 2004 Aug; 40(12):1812-24. PubMed ID: 15288282
[TBL] [Abstract][Full Text] [Related]
16. Isolated hepatic perfusion for liver metastases of malignant melanoma.
Rizell M; Mattson J; Cahlin C; Hafström L; Lindner P; Olausson M
Melanoma Res; 2008 Apr; 18(2):120-6. PubMed ID: 18337648
[TBL] [Abstract][Full Text] [Related]
17. [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
Di Filippo F; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S
Tumori; 2003; 89(4 Suppl):241-3. PubMed ID: 12903606
[TBL] [Abstract][Full Text] [Related]
18. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Grünhagen DJ; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg; 2004 Dec; 240(6):939-47; discussion 947-8. PubMed ID: 15570199
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model.
van Ijken MG; van Etten B; de Wilt JH; van Tiel ST; ten Hagen TL; Eggermont AM
J Immunother; 2000; 23(4):449-55. PubMed ID: 10916754
[TBL] [Abstract][Full Text] [Related]
20. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
